Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TRPV3 | Q8NET8 | 15/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345794 | 1.00 | GAA (0.56) | GAATRPV3CD274PDCD1PKM | |
| SCHEMBL28923686 | 0.84 | GAA (0.50) | GAATRPV3CD274PDCD1PKM | |
| SCHEMBL28923685 | 0.84 | GAA (0.50) | GAATRPV3CD274PDCD1PKM | |
| SCHEMBL28634455 | 0.82 | TRPV3 (0.48) | TRPV3CD274PDCD1LG2 | |
| SCHEMBL28634457 | 0.82 | TRPV3 (0.48) | TRPV3CD274PDCD1LG2 | |
| SCHEMBL22345797 | 0.81 | TRPV3 (0.42) | GAATRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL30850026 | 0.81 | TRPV3 (0.42) | GAATRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL29442719 | 0.81 | TRPV3 (0.42) | GAATRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL20268384 | 0.81 | TRPV3 (0.42) | GAATRPV3CD274PDCD1PDCD1LG2 | |
| SCHEMBL20268380 | 0.81 | TRPV3 (0.42) | GAATRPV3CD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4516792-A1 | BENZOTHIOPHENE COMPOUND | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023210740-A1 | BENZOTHIOPHENE COMPOUND | 第一三共株式会社 | 2023-11-02 | — | — | WO | disclosed |
| EP-3924356-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-12-22 | — | — | EP | disclosed |
| CN-113474349-A | Hydroxypyridooxazepine heptatrienes as NRF2 activators | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020165776-A1 | HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296939-A1 | BENZOTHIOPHENE COMPOUND | NFE2L2, KEAP1, BPTF | GAA 2420/4885TRPV3 1238/4885CD274 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.